These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11156542)

  • 21. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.
    Petri MA; Martin RS; Scheinberg MA; Furie RA
    Lupus; 2017 Jan; 26(1):27-37. PubMed ID: 27353505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE; Buyon JP; Kim M; Belmont HM; Mackay M; Diamond B; Marder G; Rosenthal P; Haines K; Ilie V; Abramson SB
    Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema.
    Polderman MC; Govaert JC; le Cessie S; Pavel S
    Clin Exp Dermatol; 2003 Nov; 28(6):584-7. PubMed ID: 14616819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial.
    Abdou NI; Rider V; Greenwell C; Li X; Kimler BF
    J Rheumatol; 2008 May; 35(5):797. PubMed ID: 18381791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary study of a traditional Chinese medicine formula in systemic lupus erythematosus patients to taper steroid dose and prevent disease flare-up.
    Liao YN; Liu CS; Tsai TR; Hung YC; Chang SJ; Lin HL; Chen YC; Lai HM; Yu SF; Chen CJ
    Kaohsiung J Med Sci; 2011 Jul; 27(7):251-7. PubMed ID: 21757141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.
    van Vollenhoven RF; Park JL; Genovese MC; West JP; McGuire JL
    Lupus; 1999; 8(3):181-7. PubMed ID: 10342710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
    Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
    Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
    Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.
    Bengtsson AA; Sturfelt G; Lood C; Rönnblom L; van Vollenhoven RF; Axelsson B; Sparre B; Tuvesson H; Ohman MW; Leanderson T
    Arthritis Rheum; 2012 May; 64(5):1579-88. PubMed ID: 22131101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
    Petri MA; Lahita RG; Van Vollenhoven RF; Merrill JT; Schiff M; Ginzler EM; Strand V; Kunz A; Gorelick KJ; Schwartz KE;
    Arthritis Rheum; 2002 Jul; 46(7):1820-9. PubMed ID: 12124866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement.
    Yahya F; Jasmin R; Ng CT; Cheah TE; Sockalingam S
    Int J Rheum Dis; 2013 Dec; 16(6):724-30. PubMed ID: 24119227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
    Fortin PR; Abrahamowicz M; Ferland D; Lacaille D; Smith CD; Zummer M;
    Arthritis Rheum; 2008 Dec; 59(12):1796-804. PubMed ID: 19035431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus.
    Tam LS; Li EK; Wong CK; Lam CW; Szeto CC
    Lupus; 2004; 13(8):601-4. PubMed ID: 15462490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.
    Ward MM; Marx AS; Barry NN
    J Rheumatol; 2000 Mar; 27(3):664-70. PubMed ID: 10743805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
    Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
    Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Menopause hormonal therapy in women with systemic lupus erythematosus.
    Sánchez-Guerrero J; González-Pérez M; Durand-Carbajal M; Lara-Reyes P; Jiménez-Santana L; Romero-Díaz J; Cravioto MD
    Arthritis Rheum; 2007 Sep; 56(9):3070-9. PubMed ID: 17763408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.
    Chamberlain C; Colman PJ; Ranger AM; Burkly LC; Johnston GI; Otoul C; Stach C; Zamacona M; Dörner T; Urowitz M; Hiepe F
    Ann Rheum Dis; 2017 Nov; 76(11):1837-1844. PubMed ID: 28780512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.
    Cardiel MH; Tumlin JA; Furie RA; Wallace DJ; Joh T; Linnik MD;
    Arthritis Rheum; 2008 Aug; 58(8):2470-80. PubMed ID: 18668592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.